Presenter Karl Lewis outlines the findings for adjuvant vemurafenib versus placebo in patients at high risk of recurrence after resection of BRAF V600+ advanced or metastatic melanoma.
26-09-2017 | ESMO 2017 | Video
26-09-2017 | ESMO 2017 | Video
Presenter Karl Lewis outlines the findings for adjuvant vemurafenib versus placebo in patients at high risk of recurrence after resection of BRAF V600+ advanced or metastatic melanoma.